These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37276358)

  • 1. Mitochondrial Protease Targeting Chimeras for Mitochondrial Matrix Protein Degradation.
    Wang D; Wang W; Fang L; Qi L; Zhang Y; Liu J; Liang Y; Yang H; Wang M; Wei X; Jiang R; Liu Y; Zhou W; Fang X
    J Am Chem Soc; 2023 Jun; 145(23):12861-12869. PubMed ID: 37276358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Protein Degradation via Lysosomes.
    Paudel RR; Lu D; Roy Chowdhury S; Monroy EY; Wang J
    Biochemistry; 2023 Feb; 62(3):564-579. PubMed ID: 36130224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted protein degradation in drug development: Recent advances and future challenges.
    Song J; Hu M; Zhou J; Xie S; Li T; Li Y
    Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances of targeted protein degradation technology and its applications in diseases therapy].
    Chen S; Yang H; Jiang J; Yu S; Li T; Ge S
    Sheng Wu Gong Cheng Xue Bao; 2021 Nov; 37(11):3915-3932. PubMed ID: 34841795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing targeted protein degradation for metabolic diseases therapy.
    Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
    Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial quality control via organelle and protein degradation.
    Yamano K; Kinefuchi H; Kojima W
    J Biochem; 2024 Apr; 175(5):487-494. PubMed ID: 38102729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
    Alabi SB; Crews CM
    J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway.
    Cassidy K; Zhao H
    Biochemistry; 2023 Feb; 62(3):580-587. PubMed ID: 34569233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted protein degradation directly engaging lysosomes or proteasomes.
    Kim J; Byun I; Kim DY; Joh H; Kim HJ; Lee MJ
    Chem Soc Rev; 2024 Apr; 53(7):3253-3272. PubMed ID: 38369971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Protein Degradation through E2 Recruitment.
    Forte N; Dovala D; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Nomura DK
    ACS Chem Biol; 2023 Apr; 18(4):897-904. PubMed ID: 36940189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
    Coll-Martínez B; Delgado A; Crosas B
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted protein degradation at the host-pathogen interface.
    Grohmann C; Marapana DS; Ebert G
    Mol Microbiol; 2022 Mar; 117(3):670-681. PubMed ID: 34816514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial quality control by the ubiquitin-proteasome system.
    Taylor EB; Rutter J
    Biochem Soc Trans; 2011 Oct; 39(5):1509-13. PubMed ID: 21936843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis.
    Greer YE; Hernandez L; Fennell EMJ; Kundu M; Voeller D; Chari R; Gilbert SF; Gilbert TSK; Ratnayake S; Tang B; Hafner M; Chen Q; Meerzaman D; Iwanowicz E; Annunziata CM; Graves LM; Lipkowitz S
    Cancer Res Commun; 2022 Oct; 2(10):1144-1161. PubMed ID: 36388465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.
    Lin J; Jin J; Shen Y; Zhang L; Gong G; Bian H; Chen H; Nagle DG; Wu Y; Zhang W; Luan X
    Theranostics; 2021; 11(17):8337-8349. PubMed ID: 34373745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ubiquitin-independent protein degradation in proteasomes].
    Buneeva OA; Medvedev AE
    Biomed Khim; 2018 Mar; 64(2):134-148. PubMed ID: 29723144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitin-like domains can target to the proteasome but proteolysis requires a disordered region.
    Yu H; Kago G; Yellman CM; Matouschek A
    EMBO J; 2016 Jul; 35(14):1522-36. PubMed ID: 27234297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-degron-mediated degradation and regulation of mitochondrial PINK1 kinase.
    Eldeeb MA; Ragheb MA
    Curr Genet; 2020 Aug; 66(4):693-701. PubMed ID: 32157382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifaceted targeted protein degradation systems for different cellular compartments.
    Zorca CE; Fallahi A; Luo S; Eldeeb MA
    Bioessays; 2022 Jun; 44(6):e2200008. PubMed ID: 35417040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the linkage between the ubiquitin-proteasome system and the mitochondria.
    Lehmann G; Udasin RG; Ciechanover A
    Biochem Biophys Res Commun; 2016 Apr; 473(1):80-86. PubMed ID: 26996128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.